ABIVAX : to present at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464

Paris, France January 21st 2016 - ABIVAX (Euronext Paris: FR0012333284 - ABVX), an emerging leader in developing and commercializing novel antiviral therapies for diseases like HIV/AIDS and chronic Hepatitis B (CHB), today announced the acceptance of the abstract 'Early Evidence of Antiviral Activity & Safety of ABX464 in HIV Treatment Naive Patients,' as a late-breaking news presentation by the prestigious Conference on Retroviruses and Opportunistic Infections (CROI), t0 be held February 22-25, 2016 in Boston, Massachusetts, at the Hynes Convention Center.

Abivax SA issued this content on 21 January 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 16 February 2016 15:17:25 UTC

Original Document: http://www.abivax.com/en/investors/press-releases/225-abivax-to-present-at-the-prestigious-conference-on-retroviruses-and-opportunistic-infections-croi-positive-top-line-clinical-phase-iia-data-for-novel-hiv-drug-candidate-abx464.html